Bone mineral density in postmenopausal breast cancer survivors.
OBJECTIVE
The overall purpose of this longitudinal 18-month study was to test the feasibility and effectiveness of a multicomponent intervention for prevention and treatment of osteoporosis. The purpose of this article is to describe the baseline bone mineral density (BMD) findings for 30 postmenopausal women and to compare these BMD findings to time since menopause, body mass index, and tamoxifen use.


METHODS
Baseline data of BMD findings for 30 postmenopausal women, who have had a variety of treatments including surgery, adjuvant chemotherapy and or tamoxifen, and are enrolled in the 18-month longitudinal study. A demographic questionnaire and a three day dietary record were used to collect baseline data.


CONCLUSIONS
Eighty percent of the women with breast cancer history had abnormal BMDs at baseline (t-scores below -1.00 SD). Thinner women showed a greater risk for accelerated trabecular bone loss at the spine and hip.


CONCLUSIONS
These findings suggest the need for early BMD assessments and for aggressive health promotion intervention strategies that include a multifaceted protocol of drug therapy for bone remodeling, 1500 mg of daily calcium, 400 IU vitamin D and a strength weight training program that is implemented immediately following chemotherapy treatment and menopause in this high risk population of women.
Twiss
J J
JJ
University of Nebraska Medical Center College of Nursing, Omaha, NE, USA. jtwiss@unmc.edu
Waltman
N
N
Ott
C D
CD
Gross
G J
GJ
Lindsey
A M
AM
Moore
T E
TE
D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D015992:Body Mass Index; D015519:Bone Density; D016723:Bone Remodeling; D001943:Breast Neoplasms / Q000150:complications* / Q000188:drug therapy; D002118:Calcium / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008875:Middle Aged; D010024:Osteoporosis / Q000517:prevention & control*; D017698:Postmenopause; D013629:Tamoxifen / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D014807:Vitamin D; D002118:Calcium